Your session is about to expire
← Back to Search
Tyrosine Kinase Inhibitor
TPX-0131 for Non-Small Cell Lung Cancer
Phase 1
Waitlist Available
Research Sponsored by Turning Point Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 34 months
Awards & highlights
Summary
This trial is testing a new drug to treat patients with lung cancer that has progressed or spread, and who have a specific genetic change (ALK+). The trial will assess the safety and effectiveness of the drug.
Eligible Conditions
- Non-Small Cell Lung Cancer
- Solid Tumors
- Metastatic Tumor
- Gene Mutation
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ approximately 34 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 34 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Define the Recommended Phase 2 Dose
Incidence of first cycle dose-limiting toxicities (DLTs) of TPX-0131
Secondary outcome measures
Adverse events (AEs)
Trial Design
1Treatment groups
Experimental Treatment
Group I: TPX-0131Experimental Treatment1 Intervention
The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0131.
Find a Location
Who is running the clinical trial?
Turning Point Therapeutics, Inc.Lead Sponsor
9 Previous Clinical Trials
866 Total Patients Enrolled
Eric Park, M.D.Study DirectorTurning Point Therapeutics
1 Previous Clinical Trials
90 Total Patients Enrolled
Turning Point Therapeutics, MDStudy DirectorTurning Point Therapeutics
3 Previous Clinical Trials
125 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger